Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
ProShares Ultra Nasdaq Biotechnology (BIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/29/2025: BIB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit -4.82% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/29/2025 |
Key Highlights
Volume (30-day avg) - | Beta 1.16 | 52 Weeks Range 33.65 - 68.43 | Updated Date 06/29/2025 |
52 Weeks Range 33.65 - 68.43 | Updated Date 06/29/2025 |
Upturn AI SWOT
ProShares Ultra Nasdaq Biotechnology
ETF Overview
Overview
ProShares Ultra Nasdaq Biotechnology (BIB) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. It offers leveraged exposure to biotechnology companies listed on the Nasdaq.
Reputation and Reliability
ProShares is a well-known issuer specializing in leveraged and inverse ETFs, recognized for its expertise in providing targeted exposure to specific market segments.
Management Expertise
ProShares has a dedicated team with significant experience in managing leveraged and inverse investment products, utilizing sophisticated strategies to track index performance.
Investment Objective
Goal
To achieve daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index.
Investment Approach and Strategy
Strategy: The ETF employs a leveraged strategy, aiming to deliver twice the daily return of the Nasdaq Biotechnology Index using derivatives such as swap agreements.
Composition The ETF's composition primarily consists of financial instruments (derivatives) designed to provide leveraged exposure to the stocks within the Nasdaq Biotechnology Index.
Market Position
Market Share: Difficult to assess precise market share due to the nuances of leveraged ETFs, but BIB holds a significant position among leveraged biotech ETFs.
Total Net Assets (AUM): 226000000
Competitors
Key Competitors
- LABU
- BIS
- XBI
Competitive Landscape
The competitive landscape includes other leveraged and unleveraged biotechnology ETFs. BIB offers 2x leverage, appealing to traders seeking amplified returns but with increased risk. LABU offers 3x leverage, XBI provides unleveraged exposure to a broad basket of biotech stocks, and BIS offers inverse exposure.
Financial Performance
Historical Performance: Historical performance can vary significantly due to the leveraged nature of the ETF. Past performance is not indicative of future results.
Benchmark Comparison: The ETF's performance is benchmarked against two times the daily performance of the Nasdaq Biotechnology Index.
Expense Ratio: 0.95
Liquidity
Average Trading Volume
The average trading volume of BIB is generally high, indicating good liquidity.
Bid-Ask Spread
The bid-ask spread can vary depending on market conditions but is usually reasonable for a leveraged ETF.
Market Dynamics
Market Environment Factors
Economic indicators, biotech sector growth, FDA approvals, and clinical trial results significantly affect BIB's performance.
Growth Trajectory
Growth trajectory depends on the overall performance of the Nasdaq Biotechnology Index and investor appetite for leveraged products; strategy changes are infrequent.
Moat and Competitive Advantages
Competitive Edge
BIB's primary advantage is its 2x leveraged exposure to the Nasdaq Biotechnology Index, offering traders the opportunity to amplify potential gains or losses. This unique feature differentiates it from unleveraged biotech ETFs. ProShares' experience in managing leveraged ETFs also contributes to its competitive edge. However, leveraged ETFs are only suitable for short-term investments and are not intended for buy-and-hold strategies.
Risk Analysis
Volatility
BIB exhibits high volatility due to its leveraged nature, making it suitable only for risk-tolerant investors.
Market Risk
Market risks include sector-specific risks (e.g., regulatory changes, drug trial failures) and general market risks (e.g., economic downturns).
Investor Profile
Ideal Investor Profile
The ideal investor is a sophisticated, short-term trader seeking to capitalize on short-term movements in the biotech sector and understands the risks associated with leveraged products.
Market Risk
BIB is best suited for active traders with a short-term investment horizon, not for long-term investors or passive index followers.
Summary
ProShares Ultra Nasdaq Biotechnology (BIB) is a leveraged ETF designed for short-term trading of the Nasdaq Biotechnology Index. Its 2x leverage amplifies both gains and losses, making it a high-risk, high-reward investment. It is suitable for sophisticated traders with a deep understanding of the biotech sector and leveraged instruments. Due to its leveraged nature, it is not appropriate for long-term investors or those with a low risk tolerance. Potential investors must carefully consider the implications of compounding and daily resets inherent in leveraged ETFs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ProShares Website
- ETF.com
- Yahoo Finance
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results. Leveraged ETFs are not suitable for all investors. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProShares Ultra Nasdaq Biotechnology
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.